The rapid and accurate genotyping system for MYD88 L265P and CD79B Y196 mutations that we developed in this study will enable reliable rapid molecular diagnosis and early prediction of response to R‐MPV, which might help to determine the best treatment strategy for PCNSL. Here, MYD88 is linked to primary central nervous system lymphoma.